Tag:

Shire

Latest Headlines

Latest Headlines

BioMarin shares climb on Shire takeover buzz

The M&A rumor mill was churning Friday morning on reports of an in-the-works Shire ($SHPG) deal for orphan drugmaker BioMarin Pharmaceuticals.

Shire, BioMarin and the snowball effect of buyout rumors

Shire is an acquisitive company with a focus on rare diseases. BioMarin fits the same description. A blog post that, by its own admission, "might be codswallop," reported that the former is considering buying the latter. And those three facts combined to send the shares of BioMarin, far from a penny stock, up as much as 15% on Friday, illustrating how the biotech boom has changed Wall Street's perception of the drug industry.

Which diseases are driving drug spending hikes? It's not just hep C

Industry watchers well know that U.S. drug spending is rising--a lot. And they also know that it's likely to continue over the next few years if some major changes don't occur. But which medical conditions will be responsible for the swelling tide? Some of those may surprise you.

Endo's shown it's willing to spend. But with Salix gone, what's left worth buying?

As Endo showed last week with its failed $10 billion bid for North Carolina's Salix, it's willing to shell out some serious dough if the right target comes along. The question is, what's left?

UPDATED: Clearing out of Pennsylvania, Shire warns of expected 'mass layoff'

Shire is pushing ahead with plans to shift hundreds of workers out of Pennsylvania and into its Boston-area headquarters. The biotech filed notice with the state of Pennsylvania that it is downsizing its operations at its Chesterbrook, PA, campus by 600 staffers. And the company is confirming that the bulk of those jobs are headed to Lexington, MA.

Chronic disease therapies dominate top-selling drugs in Taiwan

Seventy percent of the 20 best-selling drugs in Taiwan are for treating blood pressure, strokes and other chronic diseases.

Startup Akili partners with nonprofit Autism Speaks to test video game

Akili Interactive Labs has partnered with the nonprofit Autism Speaks to conduct a clinical trial of its cognitive assessment and personalized treatment video game.

As Shire gears up to push Vyvanse for binge eating, critics worry about abuse

Shire is pushing full steam ahead to get the word out on binge eating disorder, the new indication it snagged for blockbuster Vyvanse last month.

UPDATED: Shire's Vyvanse brand team draws fire for aggressive binge-eating push

Shire is pushing full steam ahead to get the word out on binge eating disorder, the new indication it snagged for blockbuster Vyvanse last month. But some doctors think the Dublin drugmaker may be taking the marketing a bit too far, considering Vyvanse's abuse potential.

Shire's shopping spree continues with a $245M deal to buy PhIII-ready Meritage

Fresh from completing a $5 billion deal for NPS Pharma, Shire stopped to bag a small San Diego biotech, picking up Meritage Pharma and a Phase III-ready rare disease drug for $70 million upfront and a slate of unspecified milestones.